Treating Bone Metastases with Local Therapy in a Breast Cancer Patient Resulted in Decreased Pain and Prevented Fracture

References

• Li S , PengY , WeinhandlEDet al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin. Epidemiol.4, 87–93 (2012).
   PubMedGoogle Scholar
• Macedo F , LadeiraK , PinhoFet al. Bone metastases: an overview. Oncol. Rev.11, 321 (2017).
   PubMed Web of Science ®Google Scholar
• Kennecke H , YerushalmiR , WoodsRet al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol.28, 3271–3277 (2010).
   PubMed Web of Science ®Google Scholar
• Pulido C , VendrellI , FerreiraARet al. Bone metastasis risk factors in breast cancer. Ecancermedicalscience11, 715 (2017).
   PubMedGoogle Scholar
• Hong S , YoukT , LeeSJ , KimKM , VajdicCM. Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study. PLOS One15, e0234927 (2020).
   PubMed Web of Science ®Google Scholar
• Kingsley LA , FournierPG , ChirgwinJM , GuiseTA. Molecular biology of bone metastasis. Mol. Cancer Ther.6, 2609–2617 (2007).
   PubMed Web of Science ®Google Scholar
• Bongiovanni A , FocaF , FantiniMet al. First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Sci Rep.11, 4329 (2021).
   PubMed Web of Science ®Google Scholar
• Schneider G , VoltzR , GaertnerJ. Cancer pain management and bone metastases: an update for the clinician. Breast Care7, 113–120 (2012).
   PubMed Web of Science ®Google Scholar
• Goblirsch MJ , ZwolakPP , ClohisyDR. Biology of bone cancer pain. Clin. Cancer Res.12(20 Pt 2), 6231S–6235S (2006).
   PubMed Web of Science ®Google Scholar
• von Moos R , CostaL , RipamontiCI , NiepelD , SantiniD. Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur. J. Cancer71, 80–94 (2017).
   PubMed Web of Science ®Google Scholar
• Onitilo AA , EngelJM , GreenleeRT , MukeshBN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res7, 4–13 (2009).
   PubMedGoogle Scholar
• Parise CA , CaggianoV. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J. Cancer Epidemiol.2014,10.1155/2014/469251 (2014).
   PubMedGoogle Scholar
• Yasui Y , PotterJD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control10, 431–437 (1999).
   PubMed Web of Science ®Google Scholar
• Arpino G , WeissH , LeeAVet al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst.97, 1254–1261 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao H , GongY. The prognosis of single hormone receptor-positive breast cancer stratified by HER2 status. Front. Oncol.11,10.3389/fonc.2021.643956 (2021).
   Web of Science ®Google Scholar
• Rubin I , YardenY. The basic biology of HER2. Ann. Oncol.12(Suppl. 1), S3–S8 (2001).
   PubMed Web of Science ®Google Scholar
• Reinert T , de PaulaB , ShafaeeMN , SouzaPH , EllisMJ , BinesJ. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. Chin. Clin. Oncol.7, 25 (2018).
   PubMedGoogle Scholar
• Hart CD , MigliaccioI , MalorniL , GuarducciC , BiganzoliL , DiLeo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat. Rev. Clin. Oncol.12, 541–552 (2015).
   PubMed Web of Science ®Google Scholar
• Thakur NA , DeBoyaceSD , MarguliesBS. Antagonism of the met5-enkephalin-opioid growth factor receptor-signaling axis promotes MSC to differentiate into osteoblasts. J. Orthop. Res.34, 1195–1205 (2016).
   PubMed Web of Science ®Google Scholar
• Sasaki A , BoyceBF , StoryBet al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res.55, 3551–3557 (1995).
   PubMed Web of Science ®Google Scholar
• Roodman GD . Regulation of osteoclast differentiation. Ann. NY Acad. Sci.1068, 100–109 (2006).
   PubMed Web of Science ®Google Scholar
• Chiechi A , WaningDL , StayrookKR , BuijsJT , GuiseTA , MohammadKS. Role of TGF-β in breast cancer bone metastases. Adv. Biosci. Biotechnol.4, 15–30 (2013).
   PubMedGoogle Scholar
• Margulies BS , DeBoyaceSD , DamronTA , AllenMJ. Ewing’s sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing’s sarcoma of bone. Bone79, 121–130 (2015).
   PubMed Web of Science ®Google Scholar
• Rizzo SE , KenanS. Pathologic fractures. In: StatPearls.StatPearls Publishing, FL, USA (2023). www.ncbi.nlm.nih.gov/books/NBK559077/
   Google Scholar
• Saad F , LiptonA , CookR , ChenYM , SmithM , ColemanR. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer110, 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Coleman RE . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res.12(20 Pt 2), 6243S–6249S (2006).
   PubMed Web of Science ®Google Scholar
• Confavreux CB , FolletH , MittonD , PialatJB , ClézardinP. Fracture risk evaluation of bone metastases: a burning issue. Cancers13, 5711 (2021).
   PubMed Web of Science ®Google Scholar
• Adogwa O , RubioDR , BuchowskiJM , D’SouzaA , ShlykovMA , JenningsJW. Spine-specific skeletal related events and mortality in non-small cell lung cancer patients: a single-institution analysis. J. Neurosurg. Spine36, 125–132 (2022).
   PubMed Web of Science ®Google Scholar
• So A , ChinJ , FleshnerN , SaadF. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can. Urol. Assoc. J.6, 465–470 (2012).
   PubMed Web of Science ®Google Scholar
• Jensen A , JacobsenJB , NørgaardM , YongM , FryzekJP , SørensenHT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer11, 29 (2011).
   PubMed Web of Science ®Google Scholar
• Hill T , D’AlessandroP , MurrayK , YatesP. Prognostic factors following pathological fractures. ANZ J. Surg.85, 159–163 (2015).
   PubMed Web of Science ®Google Scholar
• Cho JH , HaJK , HwangCJ , LeeDH , LeeCS. Patterns of treatment for metastatic pathological fractures of the spine: the efficacy of each treatment modality. Clin. Orthop. Surg.7, 476–482 (2015).
   PubMedGoogle Scholar
• Tokuhashi Y , UeiH , OshimaM , AjiroY. Scoring system for prediction of metastatic spine tumor prognosis. World J. Orthop.5, 262–271 (2014).
   PubMedGoogle Scholar
• Howell SJ , CasbardA , CarucciMet al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol.23, 851–864 (2022).
   PubMed Web of Science ®Google Scholar
• Xie P , AnR , YuS , HeJ , ZhangH. A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape. J. Transl. Med.19, 398 (2021).
   PubMed Web of Science ®Google Scholar
• Bae SY , KimS , LeeJHet al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer15, 138 (2015).
   PubMed Web of Science ®Google Scholar